Home > Blog > Research > Equity Research: Sanofi
On July 29, 2021, Sanofi announced its second quarter 2021 results. The pharmaceutical company reported net sales growth at constant exchange rate (CER) of 12.4%, up to €8.7 billion, driven primarily by continued strong Dupixent results and increased demand for flu vaccines. On a reported basis, sales were up by 6.5%, which factor in a negative exchange rate movement of 5.9%. The negative currency movement was attributed to weakness in the US dollar, Japanese yen, Turkish lira and Argentine pesos. The top line growth inevitably resulted in higher profitability. Sanofi reported that gross profit in the second quarter increased by 13.5% at CER and business operating income was reported 13.8% higher at CER, on a comparative basis. Click here to access the report

Disclaimer

The information provided on this website is being provided solely for educational and informational purposes and should not be construed as investment advice, advice concerning particular investments or investment decisions, or tax or legal advice. Similarly, any views or opinions expressed on this website are not intended and should not be construed as being investment, tax or legal advice or recommendations. Investment advice should always be based on the particular circumstances of the person to whom it is directed, which circumstances have not been taken into consideration by the persons expressing the views or opinions appearing on this website. Calamatta Cuschieri Investment Services Ltd has not verified and consequently neither warrants the accuracy nor the veracity of any information, views, or opinions appearing on this website. You should always take professional investment advice in connection with, or independently research and verify, any information that you find or views or opinions which you read on our website and wish to rely upon, whether for the purpose of making an investment decision or otherwise. CC does not accept liability for losses suffered by persons as a result of information, views, or opinions appearing on this website.

Calamatta Cuschieri Investment Services Ltd is licensed to conduct investment services business under the Investments Services Act by the MFSA and is also registered as a Tied Insurance Intermediary under the Insurance Distribution Act.